Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

David Sallman, Amy F McLemore, Onyee Chan, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie, Alison R. Walker, David H Spencer, Rami S. Komrokji, Jeffrey E Lancet, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2024-205211

Published: 2024

Journal Articles

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul Vedula, Donna S. Neuberg, Marcio Andrade-Campos, Simon Smith, Richard M Stone, Amir T. Fathi, Matthew J. Walter, Timothy Aaron Graubert, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2024-195793

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Reduced Subclone Diversity in Clonal Cytopenia of Undetermined Significance Compared to Myelodysplastic Syndrome

Monique Chavez, Sridhar N Srivatsan, Christopher A Miller, Andrew J. Menssen, Ajay Khanna, Jin Shao, Catrina Fronick, Robert Fulton, Sharon E Heath, Constantine Logothetis, Tasha Burton, Victoria Donaldson, Claudia Cabrera, Raya Saba, Kiran R. Vij, Eric J. Duncavage, Meagan Jacoby, Matthew J. Walter

Blood (2023) 142 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2023-189591

Published: 2023

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Rachel Cook, Meagan Jacoby, Daniel Nowak, Brenda Chyla, Ying Zhou, Grace Ku, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 319.

https://doi.org/10.1182/blood-2023-189446

Published: 2023

Journal Articles

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Guillermo Garcia-Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan Jacoby, Ilona Cunningham, Karl-Anton Kreuzer, Anoop K Enjeti, Maria R. Baer, Rachel Cook, Joseph Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia

Blood (2023) 142 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2023-187102

Published: 2023

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

Blood (2018) 132 (Supplement 1): 5277.

https://doi.org/10.1182/blood-2018-99-114979

Published: 2018

Journal Articles

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Meagan Jacoby, MD, Reetom Bera, Theresa Fletcher, Mark A. Fiala, BS, Kathryn Trinkaus, PhD, John F. DiPersio, MD PhD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Daniel C. Link, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2018-99-115603

Published: 2018

Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece

Blood (2018) 131 (8): 855–863.

https://doi.org/10.1182/blood-2017-08-797886

Published: 2018

Includes: Supplemental data

Journal Articles

Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant

Meagan Jacoby, MD PhD, Eric J. Duncavage, MD, Gue Su Chang, PhD, Christopher A Miller, PhD, Jin Shao, Kevin Elliot, Joshua Robinson, Robert S Fulton, Catrina Fronick, Michelle O'Laughlin, Daniel C. Link, MD, John F DiPersio, MD PhD, Peter Westervelt, MDPhD, Timothy James J Ley, MD, Timothy Aaron Graubert, MD, Matthew J. Walter, MD

Blood (2017) 130 (Supplement 1): 4232.

https://doi.org/10.1182/blood.V130.Suppl_1.4232.4232

Published: 2017

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Eric Huselton, MD, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Meagan Jacoby, MD PhD, Iskra Pusic, MD, Rizwan Romee, MD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD

Blood (2017) 130 (Supplement 1): 5067.

https://doi.org/10.1182/blood.V130.Suppl_1.5067.5067

Published: 2017

Journal Articles

Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant

Eric J. Duncavage, MD, Meagan Jacoby, MD PhD, Gue Su Chang, PhD, Christopher A Miller, PhD, Natasha Edwin, MD, Geoffrey L. Uy, MD, Joshua Robinson, Haley J Abel, PhD, Jin Shao, Kevin Elliot, Robert Fulton, Catrina Fronick, Michelle O'Laughlin, John F DiPersio, MD PhD, Timothy J Ley, MD, Kathryn Trinkaus, PhD, Timothy Aaron Graubert, MD, Matthew J. Walter, MD

Blood (2017) 130 (Supplement 1): 1669.

https://doi.org/10.1182/blood.V130.Suppl_1.1669.1669

Published: 2017

Journal Articles

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

Blood (2017) 129 (24): 3175–3183.

https://doi.org/10.1182/blood-2016-11-750174

Published: 2017

Includes: Supplemental data

Journal Articles

A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS

Mathew A. Cherian, MD, Raoul Tibes, MD PhD, Theresa Fletcher, MS, Mark A. Fiala, BS, CCRP, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Keith E. Stockerl-Goldstein, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, John F. DiPersio, MD PhD, Ravi Vij, MD

Blood (2014) 124 (21): 1931.

https://doi.org/10.1182/blood.V124.21.1931.1931

Published: 2014

Journal Articles

Donor-to-Recipient Weight Ratio Is Independently Associated with CD34 + Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

Mark A Fiala, BS, CCRP, Soo Park, MD, Camille N. Abboud, MD, Amanda F. Cashen, MD, Meagan Jacoby, MD PhD, Iskra Pusic, MD, Rizwan Romee, MD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Ravi Vij, MBBS, MD, Peter Westervelt, MD PhD, Tanya M Wildes, MD MSCI, John F. DiPersio, MD PhD, Keith E. Stockerl-Goldstein, MD

Blood (2014) 124 (21): 2456.

https://doi.org/10.1182/blood.V124.21.2456.2456

Published: 2014

Journal Articles

Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

Blood (2014) 124 (21): 850.

https://doi.org/10.1182/blood.V124.21.850.850

Published: 2014

Journal Articles

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Lukas D. Wartman, MD, Mark A. Fiala, BS, CCRP, Emily Hawkins, BS, Theresa Fletcher, MS, Melissa Allen, Amanda F. Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD PhD, Keith E. Stockerl-Goldstein, MD, Iskra Pusic, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 5292.

https://doi.org/10.1182/blood.V124.21.5292.5292

Published: 2014

NARROW

Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Reduced Subclone Diversity in Clonal Cytopenia of Undetermined Significance Compared to Myelodysplastic Syndrome

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS

Donor-to-Recipient Weight Ratio Is Independently Associated with CD34 + Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only